title: In vivo effects of meloxicam, celecoxib, and ibuprofen on free radical metabolism in human erythrocytes.
abstract: One of the major groups of chemical mediators involved in the inflammatory response is the prostaglandins, which are synthesized from arachidonic acid by the enzyme cyclooxygenase. The aim of this study is to compare the in vivo effects of celecoxib, meloxicam, and ibuprofen on the activities of catalase (CAT), glutathione peroxidase (GSHPx), superoxide dismutase (SOD) as well as malondialdehyde (MDA), and antioxidant potential levels (AOP) in human erythrocytes. Patients diagnosed as osteoarthritis were included in the study. Patients were treated with Celecoxib (200 mg/d) (n = 12), Meloxicam (15 mg/d) (n = 12), and Ibuprufen (1200 mg/d) (n = 9) for 21 days. SOD, CAT, GSHPx activities, MDA, and AOP levels were investigated in human erythrocyte haemolysates. SOD activity and AOP levels were significantly decreased in all NSAID groups when we compared the values before and after 21 days of celecoxib, meloxicam, ibuprofen treatment. There were no significant difference in CAT, GSHPx activities, and MDA levels before and after treatment in each group. Decreased SOD activities are thought to be related with the increased superoxide anion. Decreased AOP levels may indicate impairment in the total antioxidant defence system. These NSAIDs have similar effects on free radical metabolism on human erythrocytes; despite some difference in action mechanisms.
authors.affiliation: Department of Biochemistry, Medical Faculty, Mersin University, 33079 Mersin, Turkey. mybcimen@mersin.edu.tr
authors.forename: M Y
authors.initials: MY
authors.lastname: Burak Cimen
authors.forename: Ozlem Bölgen
authors.initials: OB
authors.lastname: Cimen
authors.forename: Gülcin
authors.initials: G
authors.lastname: Eskandari
authors.forename: Günşah
authors.initials: G
authors.lastname: Sahin
authors.forename: Canan
authors.initials: C
authors.lastname: Erdoğan
authors.forename: Uğur
authors.initials: U
authors.lastname: Atik
mesh_terms: D002374:Catalase / Q000097:blood; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004912:Erythrocytes / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D016166:Free Radical Scavengers / Q000494:pharmacology*; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology*; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008315:Malondialdehyde / Q000097:blood; D000077239:Meloxicam; D008565:Membrane Proteins; D008875:Middle Aged; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D013449:Sulfonamides / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000097:blood; D013843:Thiazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D016166:Free Radical Scavengers; D007527:Isoenzymes; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013843:Thiazines; D013844:Thiazoles; D008315:Malondialdehyde; D002374:Catalase; D005979:Glutathione Peroxidase; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D013482:Superoxide Dismutase; D000068579:Celecoxib; D000077239:Meloxicam; D007052:Ibuprofen